BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 20061178)

  • 1. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
    Osada H; Kakeya H
    Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
    Rak J; Yu JL
    Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
    Ribatti D
    Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The angiogenic process as a therapeutic target in cancer.
    Bridges EM; Harris AL
    Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.
    Stegehuis JH; de Wilt LH; de Vries EG; Groen HJ; de Jong S; Kruyt FA
    Drug Resist Updat; 2010; 13(1-2):2-15. PubMed ID: 20036602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long road to colorectal cancer therapy: searching for the right signals.
    Hollande F; Pannequin J; Joubert D
    Drug Resist Updat; 2010; 13(1-2):44-56. PubMed ID: 20176501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endostatin: the logic of antiangiogenic therapy.
    Abdollahi A; Hlatky L; Huber PE
    Drug Resist Updat; 2005; 8(1-2):59-74. PubMed ID: 15939343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
    Wachsberger P; Burd R; Dicker AP
    Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
    Li H; Dkhissi F; Grenet C; Soria C; Lu H
    Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.
    Crawford Y; Ferrara N
    Trends Pharmacol Sci; 2009 Dec; 30(12):624-30. PubMed ID: 19836845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.